Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Swedbank AB

Swedbank AB boosted its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,102,974 shares of the specialty pharmaceutical company’s stock after buying an additional 28,882 shares during the period. Swedbank AB’s holdings in Jazz Pharmaceuticals were worth $187,506,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Hilltop National Bank acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $36,000. LRI Investments LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $38,000. Leonteq Securities AG acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $50,000. GoalVest Advisory LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $51,000. Finally, Danske Bank A S acquired a new position in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $40,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 1.0%

Jazz Pharmaceuticals stock opened at $228.77 on Friday. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $235.00. The company has a market cap of $14.35 billion, a PE ratio of -11,432.78, a price-to-earnings-growth ratio of 0.41 and a beta of 0.27. The stock’s 50 day moving average price is $197.18 and its 200 day moving average price is $176.51.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion for the quarter. On average, sell-side analysts predict that Jazz Pharmaceuticals PLC will post 20.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of recent research reports. Barclays boosted their target price on Jazz Pharmaceuticals from $225.00 to $234.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Robert W. Baird set a $252.00 target price on Jazz Pharmaceuticals in a report on Wednesday, May 6th. Wells Fargo & Company boosted their target price on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Leerink Partners boosted their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Finally, Truist Financial raised Jazz Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $230.56.

Insider Transactions at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,287 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $182.94, for a total value of $235,443.78. Following the sale, the chief accounting officer directly owned 6,512 shares in the company, valued at $1,191,305.28. The trade was a 16.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $194.49, for a total value of $1,039,160.07. Following the completion of the sale, the senior vice president owned 28,728 shares in the company, valued at approximately $5,587,308.72. This trade represents a 15.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 74,015 shares of company stock valued at $14,180,486. 4.30% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.